Background Fusobacterium species (spp.) bacteremia is uncommon and has been associated
with a variety of clinical presentations. We conducted a retrospective, population based …

On July 8, 2022, ACTIV-3–TICO study group published a randomised controlled trial (RCT;
ACTIV-3) 1 that evaluated tixagevimab–cilgavimab for the treatment of severe COVID-19 in …

Background Patient-level surveillance (indication, appropriate choice, dosing, route, duration)
of antimicrobial use in Canadian hospitals is needed to reduce antimicrobial overuse and …

Background: Patient-level surveillance of antimicrobial use (AMU) in Canadian hospitals
empowers the reduction of inappropriate AMU and was piloted in 2017 among 14 hospitals in …

Background Literature is scarce regarding oral step down to beta-lactams in bacteremic
urinary tract infections. Oral fluoroquinolones are an accepted and common step down for …

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare complication after
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adenoviral vector vaccination…

… Competing interests: Kevin Afra and Luke Chen are members, and David Sweet is chair,
of the BC COVID-19 Therapeutics Committee, which provides guidance on the most current …

Murray Valley encephalitis virus (MVEV), a flavivirus belonging to the Japanese encephalitis
serogroup, can cause severe clinical manifestations in humans. We report a fatal case of …

Background. Outpatient Parenteral Antimicrobial Therapy (OPAT) provides intravenous (IV)
antibiotic therapy to patients in an ambulatory setting. Typically OPAT is overseen by …

Background There has been a long-standing controversy in the infectious diseases and
microbiology community regarding the use of beta-lactam/beta-lactamase inhibitors (BLBIs) in …